Synergistic effects might be possible, as e.g., upregulation of CCK2R with consecutively improved tumor uptake after pre-treatment with the mTOR inhibitor Everolimus was reported in a preclinical study [43], as mentioned above. The gene discussed is CCKBR; the disease is neoplasm.